Thalidomide is an orally active immunomodulatory and antiangiogenic small molecule with the chemical name alpha-(N-phthalimido) glutarimide. Thalidomide is used in combination with dexamethasone to treat multiple myeloma. This medicine is also used to treat moderate to severe new lesions of leprosy and as maintenance treatment to prevent and keep erythema nodosum leprosum (skin lesions of lepr). Pharmacologically thalidomide downregulates proinflammatory cytokines such as tumor necrosis factor alpha, modulates T cell and natural killer cell activity, and reduces angiogenic signaling including VEGF and bFGF; more recently its binding to the E3 ubiquitin ligase substrate receptor cereblon has been shown to mediate degradation of transcription factors relevant to plasma cell malignancy and to contribute to teratogenicity. The molecule is chiral and undergoes in vivo racemization. Clinical use requires strict pregnancy prevention measures because of high teratogenic risk. Typical formulations are immediate release capsules or tablets with standard quality controls for potency, dissolution and residual solvents.
Parent: Thalidomide
Parent: Thalidomide
Thalidomide API and formulated products are characterized by a defined related-substance profile and stability-limited degradation products that are routinely quantified by validated HPLC, LC-MS and related analytical methods. Common related compounds and degradants include phthalimide, glutarimide-related species, hydrolytic ring-opened products, oxidative products and minor process-related intermediates; enantiomeric interconversion is an intrinsic attribute of the substance. Typical regulatory and pharmacopeial control ranges used in dossiers and monographs are individual specified related substances controlled in the range of about 0.1 to 0.5% w/w, reporting thresholds for impurities near 0.05 to 0.1% w/w, and total impurities commonly limited to about 1.0% w/w; residual solvents and elemental impurities are managed per ICH Q3C and Q3D guidance. Stability considerations include sensitivity to strong base, moisture-driven hydrolysis and potential photodegradation, so packaging and storage conditions are specified to limit impurity formation.
No, Thalidomide is not categorically banned in India. It is a controlled prescription medicine in India and is available for approved indications under strict regulatory oversight and risk-management measures to prevent fetal exposure. Importation, manufacture and distribution are subject to national regulations and prescribing programs consistent with global safety requirements.
Yes, Mat Fraser is a prominent British actor and musician born with limb differences caused by prenatal exposure to thalidomide; he has publicly identified as a thalidomide survivor and advocates on related disability and historical issues.
Thalidomide exerts multiple actions: it modulates immune responses by reducing proinflammatory cytokines such as TNF alpha, alters T cell co-stimulation, and has antiangiogenic effects by lowering VEGF and bFGF signaling. At the molecular level thalidomide and its analogs bind the cereblon component of the CRL4 E3 ubiquitin ligase complex, altering substrate selectivity and promoting ubiquitination and proteasomal degradation of transcription factors such as IKZF1 and IKZF3 in plasma cells; this cereblon-mediated activity contributes both to antineoplastic effects and to teratogenic mechanisms.
Yes, Thalidomide remains an approved therapeutic agent for specific indications, notably in combination with dexamethasone for multiple myeloma and for treatment and prevention of erythema nodosum leprosum associated with leprosy. It is also used off-label or in research settings for certain inflammatory and dermatologic conditions and some malignancies, always under strict prescribing controls and risk mitigation to prevent use in pregnancy.
